After capping off a transformative 2025, Xeris Biopharma Holdings Inc. (XERS) entered 2026 with strong commercial momentum, backed by a solid balance sheet and a disciplined strategy aimed at driving sustained long-term growth across the business. What can investors expect from Xeris this year?
The company markets Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis.
For comments and feedback contact: editorial@rttnews.com
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.